Jamieson provided advice to the management team on the structure of their reinvestment terms and new incentive arrangements in the new company set up for the purpose of making the acquisition.
Unilabs, headquartered in Geneva, and with over 5,000 employees worldwide, is one of Europe’s leading medical diagnostics businesses offering a comprehensive portfolio of diagnostic services in Europe, operating in 12 countries. Its network of facilities provides its customers with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe. Under the new ownership structure, Unilabs will be able to continue to pursue its successful M&A strategy and be at the forefront of the ongoing consolidation of the European laboratory space.
Jamieson were able to model the proposals under the new deal and provide an independent benchmark of terms according to size, geography and large market sponsor coverage. Key terms included – reinvestment amount, structure, sweet equity % and allocation, equity impact from further M&A funding.
Stuart Coventry commented: “This deal represents our sweet spot of advisory deals given our global reach and experience in transacting deals with the large sponsor houses”
